生命科学资讯

UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing

Takeda downsizes Boston footprint amid consolidation effort

‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on

Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario

Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play

GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations

Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale

Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill

Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally

Merck teams up with British medtech to boost vaginal therapeutics delivery system

AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data

Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data

Bristol Myers and Evinova pen global development partnership

FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'

FDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coils

Takeda inks $1.7B AI drug discovery deal with Iambic Therapeutics

Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena

Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'